🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 31, 2026

The two filings in the Consumer Discretionary stream present a stark contrast in capital market activity. Home Depot, a mature home improvement retailer, shows a bearish signal from a high-level insider sale, while Carvana, via its auto receivables trust, executes a complex securitization to access capital markets. The Home Depot sale, though not massive in size, is a negative sentiment indicator from a key executive. Carvana's filing is neutral, reflecting routine securitization activity to fund its used-car business, but the lack of performance data on the underlying loans introduces uncertainty. No clear sector-wide theme emerges from just two filings, but the divergence between insider selling at a stable giant and capital-raising by a growth-focused company highlights different stages of the corporate lifecycle. The absence of period-over-period comparisons or forward guidance in these filings limits trend analysis, but the insider activity at Home Depot warrants monitoring for potential broader management sentiment shifts.

2 high priority 2 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 31, 2026

The five filings for the S&P 500 Healthcare sector on this date are exclusively Form 4 insider transaction reports, providing a narrow but insightful window into management behavior. The dominant theme is a cluster of routine, non-discretionary insider transactions at Moderna, where two top executives (CFO and Chief Legal Officer) had shares withheld for tax purposes following the vesting of equity awards, indicating no active selling or buying by leadership. A more notable signal comes from Vertex Pharmaceuticals, where a director made a significant gift of 6,000 shares, which, while not a market sale, can sometimes precede or signal personal portfolio rebalancing. The only outright sale was a small, low-materiality disposition by a corporate controller at Edwards Lifesciences. The overall sentiment is neutral, with no bullish insider buying detected across the five filings. The lack of period-over-period comparisons, forward guidance, or capital allocation data in these filings limits trend analysis, but the insider activity patterns suggest a cautious status quo among healthcare executives, with no strong conviction signals either way.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — August 31, 2026

The 14 filings for the period ending August 31, 2026, reveal a deeply bifurcated market landscape. A small number of high-growth companies, led by **Super Micro Computer (SMCI)** with 77.8% revenue growth, are capitalizing on the AI infrastructure boom, while a majority of micro-cap and pre-revenue firms are exhibiting severe financial distress. A dominant theme is the 'cash burn crisis,' with 7 of 14 companies (including **CytoDyn**, **Biomerica**, and **Stimcell Energetics**) reporting widening losses, depleting cash reserves, and going-concern warnings. Period-over-period comparisons show a stark contrast: SMCI's net income more than doubled, while **CytoDyn** swung from a $3.7M profit to a $42.7M loss. Capital allocation is defensive, with no dividends or buybacks among the distressed names, while **SAIC** maintained its dividend. Insider activity was notably absent in the filings, a potential signal of management uncertainty in the smaller names. The primary actionable insight is to avoid the broad basket of cash-burning micro-caps and focus on the few companies with proven revenue growth and operational leverage, such as SMCI, while monitoring SAIC for a potential tax-driven earnings recovery.

14 high priority 14 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 31, 2026

This digest of 8 pre-analyzed SEC filings reveals a pronounced theme of capital structure stress and shareholder dilution across the small-cap and micro-cap universe, with five companies seeking shareholder approval for dilutive actions (reverse splits, massive share increases, or convertible note issuances). Period-over-period data, where available, shows a consistent pattern of cash burn and reliance on external financing, with no filing reporting organic revenue growth or margin expansion. Insider activity is notably absent across all filings, suggesting a lack of management conviction or a focus on corporate survival rather than value creation. The most material developments include the NSTS Bancorp acquisition by Brookfield Bancshares at a 14% premium to book value, the NEOS ETF Trust's change-of-control event with Goldman Sachs, and the high-risk extension vote for Spark I Acquisition Corp, which has already seen $84.8 million in redemptions. The overarching theme is a 'survival mode' environment, where shareholder value is being subordinated to corporate liquidity needs, creating both significant risks and potential special situation opportunities for activist or event-driven investors.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 31, 2026

The IPO pipeline for August 31, 2026, is dominated by a mix of traditional M&A-driven registrations (HBT Financial/Tri-County, Tempus AI/Personalis) and early-stage, high-risk IPOs (StableCoinX, La Beaute, Logoom Technologies), alongside a unique employee-focused offering from Graybar Electric. Period-over-period data reveals a stark divergence: established companies like HBT Financial and Graybar show stable financial metrics and consistent capital returns (dividends), while pre-revenue issuers (La Beaute, Logoom) exhibit zero revenue growth and deteriorating liquidity. A critical portfolio-level trend is the prevalence of 'going concern' risks and governance deficiencies among micro-cap filers, signaling a regulatory tightening environment. The most material development is the Tempus AI/Personalis merger, facing HSR Act procedural delays, which introduces near-term execution risk. Overall, the pipeline suggests a bifurcated market where seasoned issuers offer stability and yield, while speculative tech and crypto IPOs carry elevated failure risk.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — August 31, 2026

The four filings for August 31, 2026, reveal a concentrated wave of regulatory distress among small-cap US-listed companies, with three out of four firms facing imminent or actual delisting from Nasdaq or NYSE American. Northann Corp. and Cambium Networks are in advanced stages of delisting appeals or final decisions, while Microvast Holdings has entered a 180-day cure period for its sub-$1.00 bid price. In contrast, Profusa, Inc. successfully resolved a public float deficiency, demonstrating that compliance is achievable. Period-over-period data from the filings shows no revenue or margin trends, but the aggregate pattern points to heightened regulatory scrutiny and financial fragility in micro-cap equities. Insider activity and forward-looking guidance are absent across all filings, limiting predictive signals. The key actionable insight is the binary risk/reward in Microvast's cure period versus the near-certain OTC migration for Cambium Networks.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — August 31, 2026

This digest covers 36 filings from August 31, 2026, focused on US executive and director changes. A dominant theme is the acceleration of CEO succession plans, with several companies (Metallus, Greenbrier, Innventure) moving forward planned transitions, often promoting internal candidates. The filings reveal a notable uptick in insider-led investments and compensation restructurings, particularly at smaller-cap companies like Zedge and Waste Energy, which signal both conviction and potential dilution risks. A significant cluster of CFO changes (Teladoc, Charter, Expion360, RCM Technologies) and a boardroom crisis at Energy & Water Development Corp highlight governance and operational instability. While many transitions are orderly, the lack of successor naming at Herbalife and the sudden medical leave of Albany International's CFO introduce near-term uncertainty. Overall, the data points to a period of active leadership refreshment, with a mix of strategic appointments and defensive cost-cutting measures, such as TELA Bio's 18% expense reduction, indicating a focus on cash preservation and operational efficiency.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 31, 2026

The 36 filings for August 31, 2026, reveal a pronounced wave of CEO and C-suite transitions across diverse sectors, with 10 companies announcing new chief executives or presidents. While most transitions are orderly and planned, several carry significant strategic implications. Notably, insider-led investments and performance-based compensation packages at Zedge and Coherent signal strong management conviction and alignment with long-term shareholder value. However, governance concerns are acute at Energy & Water Development Corp, where a boardroom crisis erupted with a director alleging unlawful activities, and at Waste Energy Corp, where massive potential dilution looms. A clear theme of enhanced severance protections is emerging, with Sweetgreen, Americold Realty Trust, and others adopting more generous change-in-control benefits, potentially signaling heightened M&A risk or defensive positioning. The financial health of companies varies widely, with TELA Bio and Innventure undertaking aggressive cost-cutting and restructuring, while Zedge reports strong cash flow. The digest prioritizes actionable insights from these leadership changes, compensation structures, and governance events.

36 high priority 36 total filings
· daily

USA Insider Trading Pulse — August 31, 2026

The August 31, 2026, insider trading pulse reveals a market defined by starkly contrasting insider behaviors. A dominant theme is significant insider selling at high-growth tech companies like Sea Ltd and Corning, often under pre-planned 10b5-1 programs, which tempers bearish conviction. Conversely, a powerful wave of bullish insider buying is concentrated in small-cap and micro-cap names, including TDH Holdings, SCHMID Group, and Veraxa Biotech, signaling strong management conviction in undervalued plays. The data also shows a notable cluster of insider buying in the financial and real estate sectors, with Agree Realty and Matador Resources seeing director and executive purchases. Overall, the period is characterized by a bifurcation where insiders at larger, liquid names are taking profits, while those at smaller, potentially overlooked companies are aggressively deploying capital, creating a rich environment for stock-picking.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 31, 2026

The August 31, 2026 US M&A landscape is dominated by SPAC activity, with 10 of 13 filings involving blank-check companies at various stages—from IPOs (JATT III) and unit separations (NorthStrive, Samos Energy) to restatements (Breeze Acquisition II) and business combination amendments (Inflection Point V). A clear theme is the increasing complexity and risk in SPAC transactions, highlighted by a material accounting restatement at Breeze Acquisition II and a $2M funding gap at IX Acquisition Corp. In contrast, two tangible asset deals closed: Americold Realty Trust formed a $1.3B cold storage JV with EQT, and Tidewater completed its acquisition of 22 PSVs in Brazil, both signaling strategic capital deployment. The data reveals no significant period-over-period revenue or margin trends as most filings are transactional, but forward-looking data points to a catalyst-rich September with key merger deadlines and redemption windows. Insider activity is limited, though the Southern Cross Acquisition II 13D filing shows insider transfers and a 27.75% ownership stake, indicating sponsor alignment. Overall, the digest points to a bifurcated market: high-risk, cash-intensive SPACs facing execution hurdles versus asset-backed deals providing immediate operational synergies.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 31, 2026

This morning's 50 filings reveal a market bifurcated between aggressive M&A and capital deployment by large-cap firms (Aon, SLB) and significant distress signals from smaller, cash-constrained companies (Northann, Waste Energy, Breeze Acquisition). The period-over-period data highlights a clear theme of 'growth at the expense of profitability' in the services sector, with SAIC reporting 6% revenue growth but a 20% net income decline. Insider activity is a key differentiator: bullish buys at Agree Realty and Schmid Group contrast sharply with coordinated selling at Sea Ltd, where four executives sold over $2.7M in stock under 10b5-1 plans. The forward-looking data is rich with catalysts, including multiple M&A closings in September and a major patent settlement for BioMarin that creates a new royalty stream. Capital allocation patterns are also diverging, with BBVA aggressively buying back stock while Zedge suspends its repurchase program. The most actionable intelligence centers on the Aon-USI mega-deal, the Trilogy Metals strategic investment by the Department of War, and the potential for a turnaround at Alzamend Neuro following a director's $109K insider purchase.

28 high priority 22 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — August 29, 2026

The two federal construction contracts total $387.9M, both civilian, with the Department of State and Department of Transportation as the awarding agencies. The dominant theme is large-scale civilian infrastructure and institutional construction, with the highest-conviction signal being Fort Myer Construction Corp's $173M fixed-price highway reconstruction contract, which shows strong execution (93% outlaid) and low pricing risk. Caddell Construction's $214.8M State Department building contract is a material award but lacks detail on competition and pricing, presenting a neutral signal. Key risks include potential execution challenges on the fixed-price highway project and the absence of defense-related exposure, which may limit growth in a defense-heavy budget environment.

2 total filings
· daily

Defense Manufacturing Contracts — August 29, 2026

This digest covers a single, high-value $251.1 million firm-fixed-price contract awarded to Gulfstream Aerospace (a subsidiary of General Dynamics) by the Department of Commerce (NOAA) for G550 aircraft procurement. The contract is 100% civilian (NOAA), not defense-related, and represents a sole-source award with a 9-year performance period through 2028, of which $98.5 million has already been outlayed. The highest-conviction signal is the stable, long-term revenue stream for General Dynamics' Gulfstream segment, though the fixed-price structure and long duration introduce medium execution risk. Key watch items include NOAA's future budget allocations for aircraft modernization and any contract modifications that could alter the award's value or timeline.

1 total filings
· daily

VA Healthcare & Services Contracts — August 29, 2026

UnitedHealth Group's OptumRx won two identical $106.3 million firm-fixed-price delivery orders from the Department of Veterans Affairs on the same day (August 26, 2026), totaling $212.6 million in aggregate obligations for pharmacy benefit management services across two consecutive quarters (Q1 and Q2 FY25). Both contracts are civilian (0/2 defense-related), full-and-open competitive wins, signaling steady government demand for PBM services but with lumpy revenue recognition and fixed-price margin risk. The highest-conviction signal is the implied $425 million annualized run rate for VA PBM spending, though the short three-month performance periods and zero outlays to date create execution and payment uncertainty. Key risk: the firm-fixed-price structure shifts all cost risk to OptumRx, and the lack of follow-on awards beyond March 2026 leaves a revenue gap for UNH's government segment.

2 total filings
· daily

New Federal Contractors — August 29, 2026

Over the reporting period, seven new federal contracts totaling $2.17 billion were awarded, with only one defense-related contract, indicating a civilian-heavy procurement stream. The dominant theme is long-duration, civilian agency spending, led by MAXIMUS Federal Services' $892.8 million Department of Education debt management contract and Navarro Research's $427.6 million DOE environmental remediation award. The highest-conviction signal is MAXIMUS's competitive win, which provides a decade-plus revenue stream but carries fixed-price execution risk. Key watch items include the short-duration, high-risk OptumRx VA PBM orders and the potential for budget reallocations under a continuing resolution, which could impact civilian agency contract outlays.

7 total filings
· daily

Significant Contract Modifications ($10M+) — August 29, 2026

The eight contracts analyzed, totaling $2.17 billion, are overwhelmingly civilian in nature (six of eight), with only two defense-related awards. The dominant theme is stable, long-duration civilian agency spending, led by a massive $892.8 million MAXIMUS contract with the Department of Education for debt management services, which alone accounts for 41% of total obligation. The highest-conviction signal is the MAXIMUS win, a full-and-open competition that strengthens its competitive moat in government financial services. A key risk is the concentration of revenue in the MAXIMUS contract and the lumpy, short-duration $106 million OptumRx VA awards, which introduce execution and revenue visibility concerns.

8 total filings
· daily

Contract Deobligations Alert — August 29, 2026

This digest covers $2.17 billion in government obligations across 8 contracts, with only 2 defense-related awards (totaling ~$569K from DHS/ICE) and 6 civilian contracts dominating the aggregate. The highest-conviction signal is MAXIMUS FEDERAL SERVICES' $892.8 million firm-fixed-price contract with the Department of Education for debt management, representing a long-term, competitive win that underscores sustained federal investment in student loan collections. A key risk is the short-duration, high-concentration exposure for UnitedHealth Group's OptumRx, which won two $106 million VA delivery orders for a single quarter each, creating lumpy revenue and margin pressure under fixed-price terms. Investors should monitor MAXIMUS for follow-on renewals and UnitedHealth for VA Q2-Q4 PBM awards to assess recurring revenue stability.

8 total filings
· daily

Contract Option Exercises — August 29, 2026

This digest covers $2.17 billion in total obligations across 8 contract actions, with a heavy civilian tilt (6 of 8 contracts) and only 2 defense-related awards. The dominant theme is stable, long-duration civilian services: MAXIMUS INC’s $892.8 million Department of Education debt management contract and Navarro Research’s $427.6 million DOE legacy management award represent over 60% of total value. The highest-conviction signal is MAXIMUS’s competitive win in a full-and-open competition, indicating a strong moat in government financial services. Key risks include concentration in civilian agencies vulnerable to budget sequestration, and the fixed-price structure on four of the largest contracts, which introduces execution risk if costs overrun. Investors should watch the outlay pace on the Navarro contract, where only 23% has been spent, and monitor follow-on VA PBM awards for UnitedHealth Group’s OptumRx.

8 total filings
· daily

All DOE Contracts — August 29, 2026

This digest covers a single, large Department of Energy (DOE) contract awarded to Navarro Research and Engineering, Inc., valued at $427.6 million, making it a purely civilian award with no defense-related exposure. The contract, a cost-plus-award-fee arrangement for long-term surveillance, IT, and program support for the Office of Legacy Management, signals a stable, long-term revenue stream for the contractor, though only $97.1 million has been outlayed to date, leaving ~$330.5 million in potential future revenue. The highest-conviction signal is the bullish outlook for Navarro, given the contract's duration through 2021 and the low-risk cost-plus structure, but the key risk is the slow outlay rate, which suggests revenue recognition may be back-end loaded or subject to budget constraints. Investors should monitor DOE's Office of Legacy Management funding and any contract modifications or extensions as key catalysts.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 29, 2026

Across seven mega-contracts worth $2.17 billion, the vast majority are civilian agency awards (6 of 7), led by a dominant $892.8 million Department of Education debt management contract to MAXIMUS INC. Defense-related awards are notably absent—only one contract touches defense-adjacent (NOAA aircraft for General Dynamics). The highest-conviction signal is MAXIMUS's decade-plus, fixed-price win, though its performance risk is material. A key risk is near-term lumpy revenue concentration at UnitedHealth Group (OptumRx), which secured $212.6 million in two three-month VA PBM delivery orders with no outlays yet. Overall, the digest points to steady civilian demand for operational services and specialized aviation, but with limited defense exposure and execution risk on fixed-price structures.

7 total filings